The Asia Pacific Hearing Loss Disease Treatment Market would witness market growth of 5.0% CAGR during the forecast period (2022-2028).
Hearing aid devices have gained traction during the past few years as frequency of hearing loss & deafness has grown. The increasing burden of the elderly population is further anticipated to rise the demand for hearing aid devices in the coming years. This is due to possibility of increasing occurrence presbycusis, also known as age-related hearing loss, which develops slowly as a person becomes old.
Conductive hearing loss treatment choice generally includes medical involvement from an ENT specialist to confront the particular cause. Conductive hearing loss generally occurs when something prevents sound from reaching the inner ear.
China is considered one of the quickly aging populations in the world. Owing to declining fertility rates and prolonged life expectancy, the population of people above 60 years of age in China is expected to reach 28% by 2040. This profound demographic change offers various new opportunities & challenges for public health & socioeconomic growth. Also, it was observed that there was an increase in age-related hearing loss cases because of the growing aging population in Japan. In addition, Japan is also witnessing an increase in the number of youngsters with hearing problems due to stress & noise-induced hearing loss. The rise in hearing loss patients and the aging population will increase demand for the hearing loss disease treatment market in the upcoming years.
The China market dominated the Asia Pacific Hearing Loss Disease Treatment Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $1,299.7 Million by 2028.The Japan market is experiencing a CAGR of 4.4% during (2022 - 2028). Additionally, The India market would display a CAGR of 5.6% during (2022 - 2028).
Based on Disease Type, the market is segmented into Sensorineural, Conductive and Mixed. Based on Product, the market is segmented into Devices and Drugs. Based on End-user, the market is segmented into Otology Clinics, Hospitals and Ambulatory Clinics. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Novartis AG, Astellas Pharma, Inc, WS Audiology A/S, Otonomy, Inc, Sensorion, Frequency Therapeutics, Inc, Acousia Therapeutics GmbH, Pipeline Therapeutics, Inc, Audina Hearing Instruments, Inc, and Audifon GmbH & CO. KG.
Hearing aid devices have gained traction during the past few years as frequency of hearing loss & deafness has grown. The increasing burden of the elderly population is further anticipated to rise the demand for hearing aid devices in the coming years. This is due to possibility of increasing occurrence presbycusis, also known as age-related hearing loss, which develops slowly as a person becomes old.
Conductive hearing loss treatment choice generally includes medical involvement from an ENT specialist to confront the particular cause. Conductive hearing loss generally occurs when something prevents sound from reaching the inner ear.
China is considered one of the quickly aging populations in the world. Owing to declining fertility rates and prolonged life expectancy, the population of people above 60 years of age in China is expected to reach 28% by 2040. This profound demographic change offers various new opportunities & challenges for public health & socioeconomic growth. Also, it was observed that there was an increase in age-related hearing loss cases because of the growing aging population in Japan. In addition, Japan is also witnessing an increase in the number of youngsters with hearing problems due to stress & noise-induced hearing loss. The rise in hearing loss patients and the aging population will increase demand for the hearing loss disease treatment market in the upcoming years.
The China market dominated the Asia Pacific Hearing Loss Disease Treatment Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $1,299.7 Million by 2028.The Japan market is experiencing a CAGR of 4.4% during (2022 - 2028). Additionally, The India market would display a CAGR of 5.6% during (2022 - 2028).
Based on Disease Type, the market is segmented into Sensorineural, Conductive and Mixed. Based on Product, the market is segmented into Devices and Drugs. Based on End-user, the market is segmented into Otology Clinics, Hospitals and Ambulatory Clinics. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Novartis AG, Astellas Pharma, Inc, WS Audiology A/S, Otonomy, Inc, Sensorion, Frequency Therapeutics, Inc, Acousia Therapeutics GmbH, Pipeline Therapeutics, Inc, Audina Hearing Instruments, Inc, and Audifon GmbH & CO. KG.
Scope of the Study
Market Segments Covered in the Report:
By Disease Type
- Sensorineural
- Conductive
- Mixed
By Product
- Devices
- Drugs
By End-user
- Otology Clinics
- Hospitals
- Ambulatory Clinics
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Novartis AG
- Astellas Pharma, Inc
- WS Audiology A/S
- Otonomy, Inc
- Sensorion
- Frequency Therapeutics, Inc
- Acousia Therapeutics GmbH
- Pipeline Therapeutics, Inc
- Audina Hearing Instruments, Inc
- Audifon GmbH & CO. KG
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Hearing Loss Disease Treatment Market, by Disease Type
1.4.2 Asia Pacific Hearing Loss Disease Treatment Market, by Product
1.4.3 Asia Pacific Hearing Loss Disease Treatment Market, by End-user
1.4.4 Asia Pacific Hearing Loss Disease Treatment Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Strategies Deployed in Hearing Loss Disease Treatment Market
Chapter 4. Asia Pacific Hearing Loss Disease Treatment Market by Disease Type
4.1 Asia Pacific Sensorineural Market by Country
4.2 Asia Pacific Conductive Market by Country
4.3 Asia Pacific Mixed Market by Country
Chapter 5. Asia Pacific Hearing Loss Disease Treatment Market by Product
5.1 Asia Pacific Devices Market by Country
5.2 Asia Pacific Drugs Market by Country
Chapter 6. Asia Pacific Hearing Loss Disease Treatment Market by End-user
6.1 Asia Pacific Otology Clinics Market by Country
6.2 Asia Pacific Hospitals Market by Country
6.3 Asia Pacific Ambulatory Clinics Market by Country
Chapter 7. Asia Pacific Hearing Loss Disease Treatment Market by Country
7.1 China Hearing Loss Disease Treatment Market
7.1.1 China Hearing Loss Disease Treatment Market by Disease Type
7.1.2 China Hearing Loss Disease Treatment Market by Product
7.1.3 China Hearing Loss Disease Treatment Market by End-user
7.2 Japan Hearing Loss Disease Treatment Market
7.2.1 Japan Hearing Loss Disease Treatment Market by Disease Type
7.2.2 Japan Hearing Loss Disease Treatment Market by Product
7.2.3 Japan Hearing Loss Disease Treatment Market by End-user
7.3 India Hearing Loss Disease Treatment Market
7.3.1 India Hearing Loss Disease Treatment Market by Disease Type
7.3.2 India Hearing Loss Disease Treatment Market by Product
7.3.3 India Hearing Loss Disease Treatment Market by End-user
7.4 South Korea Hearing Loss Disease Treatment Market
7.4.1 South Korea Hearing Loss Disease Treatment Market by Disease Type
7.4.2 South Korea Hearing Loss Disease Treatment Market by Product
7.4.3 South Korea Hearing Loss Disease Treatment Market by End-user
7.5 Singapore Hearing Loss Disease Treatment Market
7.5.1 Singapore Hearing Loss Disease Treatment Market by Disease Type
7.5.2 Singapore Hearing Loss Disease Treatment Market by Product
7.5.3 Singapore Hearing Loss Disease Treatment Market by End-user
7.6 Malaysia Hearing Loss Disease Treatment Market
7.6.1 Malaysia Hearing Loss Disease Treatment Market by Disease Type
7.6.2 Malaysia Hearing Loss Disease Treatment Market by Product
7.6.3 Malaysia Hearing Loss Disease Treatment Market by End-user
7.7 Rest of Asia Pacific Hearing Loss Disease Treatment Market
7.7.1 Rest of Asia Pacific Hearing Loss Disease Treatment Market by Disease Type
7.7.2 Rest of Asia Pacific Hearing Loss Disease Treatment Market by Product
7.7.3 Rest of Asia Pacific Hearing Loss Disease Treatment Market by End-user
Chapter 8. Company Profiles
8.1 Novartis AG
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Segmental and Regional Analysis
8.1.4 Research & Development Expense
8.2 Astellas Pharma, Inc.
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Regional Analysis
8.2.4 Research & Development Expense
8.2.5 Recent strategies and developments:
8.2.5.1 Partnerships, Collaborations, and Agreements:
8.3 WS Audiology A/S
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Regional Analysis
8.3.4 Research & Development Expenses
8.3.5 Recent strategies and developments:
8.3.5.1 Partnerships, Collaborations, and Agreements:
8.4 Otonomy, Inc.
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Research & Development Expenses
8.4.4 Recent strategies and developments:
8.4.4.1 Partnerships, Collaborations, and Agreements:
8.5 Sensorion
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Research & Development Expenses
8.5.4 Recent strategies and developments:
8.5.4.1 Partnerships, Collaborations, and Agreements:
8.6 Frequency Therapeutics, Inc
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Research & Development Expenses
8.6.4 Recent strategies and developments:
8.6.4.1 Partnerships, Collaborations, and Agreements:
8.7 Acousia Therapeutics GmbH
8.7.1 Company Overview
8.8 Pipeline Therapeutics, Inc
8.8.1 Company Overview
8.9 Audina Hearing Instruments, Inc.
8.9.1 Company Overview
8.10. Audifon GmbH & CO. KG
8.10.1 Company Overview
Companies Mentioned
- Novartis AG
- Astellas Pharma, Inc
- WS Audiology A/S
- Otonomy, Inc
- Sensorion
- Frequency Therapeutics, Inc
- Acousia Therapeutics GmbH
- Pipeline Therapeutics, Inc
- Audina Hearing Instruments, Inc
- Audifon GmbH & CO. KG
Methodology
LOADING...
